SCHEMBL623694

SCHEMBL623694

Cn1nc2ccccc2c1C(=O)N1CCN(c2cc(OCC(F)(F)F)ncn2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.42
ACACB O00763 1/20 0.40
PDE2A O00408 1/20 0.40
HRH4 Q9H3N8 1/20 0.38
LMNA P02545 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP2C9 P11712 1/20 0.37
ALDH1A1 P00352 4/20 0.37
HTT P42858 2/20 0.37
MAPT P10636 2/20 0.37
GAA P10253 1/20 0.37
TP53 P04637 2/20 0.36
CCKAR P32238 1/20 0.36
MAPK1 P28482 2/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622565 0.86 MGLL (0.43) RAB9APDE2AHRH4LMNASMN1; SMN2
SCHEMBL624639 0.84 DRD2 (0.51) RAB9AACACBPDE2AHRH4LMNA
SCHEMBL624230 0.82 PDE2A (0.46) RAB9AACACBPDE2ALMNAKDM4E
SCHEMBL623698 0.80 P2RY12 (0.45) RAB9ALMNAKDM4EMEN1KMT2A
SCHEMBL624216 0.80 RAB9A (0.42) RAB9AACACBHRH4LMNASMN1; SMN2
SCHEMBL623899 0.79 PTK2 (0.51) RAB9AACACBLMNASMN1; SMN2KDM4E
SCHEMBL623245 0.79 TSHR (0.53) RAB9ASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL623298 0.78 PKM (0.43) RAB9AACACBHRH4LMNASMN1; SMN2
SCHEMBL624183 0.78 ACACB (0.41) RAB9AACACBSMN1; SMN2KDM4EALDH1A1
SCHEMBL624545 0.77 RBP4 (0.49) LMNAMEN1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G RAB9A 2419/4885ACACB 544/4885PDE2A 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.